3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
4
Gynecologic
2
Tumor-Agnostic
1
Thoracic
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
140
pembrolizumab
119
Carboplatin
104
Bevacizumab
90
Cisplatin
67
Specimen Handling
62
Magnetic Resonance Spectroscopy
51
olaparib
50
Gemcitabine
39
Nivolumab
36
Biopsy
36
liposomal doxorubicin
32
Taxes
31
Cyclophosphamide
31
Blood Specimen Collection
29
niraparib
27
lenvatinib
26
Letrozole
26
Doxorubicin
26
Topotecan
25
Drug Therapy
25
Immunoglobulin G
22
fludarabine
21
atezolizumab
21
Radiotherapy
21
Brachytherapy
21
Disulfides
20
durvalumab
19
Surveys and Questionnaires
19
dostarlimab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
bemarituzumab
×
Gynecologic
×
1 year
×
Clear all
NCT07146919
2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2
Withdrawn
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled